Comparative Pharmacology
Head-to-head clinical analysis: APRESOLINE ESIDRIX versus LANORINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRESOLINE ESIDRIX versus LANORINAL.
APRESOLINE-ESIDRIX vs LANORINAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apresoline (hydralazine) is a direct-acting vasodilator that relaxes arteriolar smooth muscle via unknown mechanism; Esidrix (hydrochlorothiazide) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule.
LANORINAL is a combination product containing acetaminophen, which inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors via its metabolite AM404; and butalbital, a barbiturate that enhances GABA-A receptor activity, producing sedative and anxiolytic effects.
Hydralazine (Apresoline): Oral, initial 10 mg 4 times daily for first 2-4 days, then increase to 25 mg 4 times daily for first week, then 50 mg 4 times daily thereafter. Maximum daily dose: 300 mg. Hydrochlorothiazide (Esidrix): Oral, initial 12.5-25 mg once daily, may increase to 50 mg once daily if needed.
1-2 mg intravenously or intramuscularly every 2-4 hours as needed for pain.
None Documented
None Documented
Hydralazine: 2-8 h (prolonged in renal impairment); Hydrochlorothiazide: 6-15 h (mean 10 h, increased in renal failure).
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in hepatic impairment.
Renal: Hydralazine 85-90% as metabolites, 5-10% unchanged; Hydrochlorothiazide 95% as unchanged drug. Biliary/fecal: Hydralazine <10%.
Renal: 30-50% unchanged; fecal/biliary: 50-70% as metabolites.
Category C
Category C
Antihypertensive
Antihypertensive